Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing – Animal or plant cell
Reexamination Certificate
1997-06-20
2004-04-06
Schwadron, Ronald B. (Department: 1644)
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
Animal or plant cell
C424S093100, C424S093700, C435S325000, C435S366000, C435S372000, C435S372300
Reexamination Certificate
active
06716425
ABSTRACT:
FIELD OF THE INVENTION
The invention relates generally to the treatment of cancers, and more specifically to methods which prevent recurrence of cancer.
BACKGROUND OF THE INVENTION
Adoptive transfer therapy for the treatment of cancer has been described. One such method makes use of a lethally irradiated human T cell line (TALL-104), (CD3/TCR&agr;&bgr;
+
CD8
+
CD16
−
) [A. Cesano et al,
In Vitro Cell. Dev. Biol
., 28A:648 (1992); A. Cesano et al,
J. Immunol
., 151:2943-2957 (1993); and A. Cesano et al,
Cancer Immunol. Immunoth
., 40:139 (1995)], which is endowed with MHC non-restricted killer activity against a broad range of tumors across several species, while sparing cells from normal tissues.
To date, the use of this TALL-104 cell line in such adoptive transfer has been described as requiring an immunosuppressed patient. For example, use of this cell has been described in studies in immunodeficient and immunocompetent murine models with transplantable tumors and in canines with spontaneously arising cancers [A. Cesano et al,
J. Clin. Invest
., 94:1076 (1994); A. Cesano et al,
Cancer Res
., 55:96 (1995); A. Cesano et al,
Cancer Res
., 56:3021 (1996); and A. Cesano et al,
Cancer Res
., 56:4444-4452 (1996)]. The latter two publications describe the administration of cyclosporin A to pharmacologically immunosuppress the cancer patient, to avoid rejection of the allogeneic TALL-104 effector cells.
Improved methods of treating cancers are needed in the art, and particularly methods in which a patient can receive a therapeutic anti-cancer agent without additionally receiving an immunosuppressive agent.
SUMMARY OF THE INVENTION
The invention provides a method of treating cancer, and particularly, for preventing recurrence of cancer. This method involves the step of administering an effective amount of modified TALL-104 cells to a mammalian cancer patient in the absence of an immunosuppressive agent. This first administration step may be repeated as needed, desirably for a selected number of consecutive days or one to two days following the previous administration. Optionally, a booster may be administered approximately one month following the completion of the course of treatment. Desirably, the patient undergoes therapy with the method of the invention following completion of conventional cancer therapy.
Other aspects and advantages of the present invention are described further in the following detailed description of the preferred embodiments thereof.
REFERENCES:
patent: 5166059 (1992-11-01), Paston et al.
patent: 5272082 (1993-12-01), Santoli et al.
A. Cesano et al, “Antitumor Efficacy of a Human Major Histocompatibility Complex Nonrestricted Cytotoxic T-Cell Line (TALL-104) in Immunocompetent Mice Bearing Syngeneic Leukemia”,Cancer Research,56:4444-4452 (Oct. 1, 1996).
A. Cesano et al, “Phase I Clinical Trial with a Human Major Compatibility Complex Nonrestricted Cytotoxic T-Cell Line (TALL-104) in dogs with Advanced Tumors”,Cancer Research,56:3021-3029 (Jul. 1, 1996).
A. Cesano et al, “Effects of Lethal Irradiation and Cyclosporin A Treatment on the Growth and Tumoricidal Activity of a T Cell Clone Potentially Useful in Cancer Therapy”,Cancer Immunol. Immunother.,40:139-151 (Mar. 1995).
A. Cesano et al, “Reversal of Acute Myelogenous Leukemia in Humanized SCID Mice Using a Novel Adoptive Transfer Approach”,J. Clin. Invest.,94:1076-1084 (Sep. 1994).
A. Cesano et al, “Synergistic Effects of Adriamycin and TALL-104 Cell Therapy Against a Human Gastric Carcinoma in Vivo”,Anticancer Research,17:1887-1892 (May-Jun. 1997).
A. Cesano et al, “Toxicological and Immunological Evaluation of the MHC-non-restricted Cytotoxic T Cell Line TALL-104”,Cancer Immunol. Immunother.,44:125-136 (May 1997).
S. Visonneau et al, “Cell Therapy of a Highly Invasive Human Breast Carcinoma Implanted in Immunodeficient (SCID) Mice”,Clinical Cancer Research,3:1491-1500 (Sep. 1997).
S. Visonneau et al, “Successful Treatment of Canine Malignant Histocytosis with the Human Major Histocompatibility Complex Nonrestricted Cytotoxic T-Cell Line TALL-104”,Clinical Cancer Research,3:1789-1797 (Oct. 1997).
S. Chan et al, “Mechanisms of Interferon-&ggr; Induction by Natural Killer Cell Stimulatory Factor (NKSF): Role of Transcription and mRNA Stability in the Synergistic Interactions Between NKSF and Interleukin-2”,J. Immunol.,148(1):92-98 (Jan. 1, 1992).
D. Santoli et al, “Synergistic and Antagonistic Effects of IL-1&agr; and IL-4, Respectively, on the IL-2-Dependent Growth of a T Cell Receptor-&ggr;&dgr;+Human T Leukemia Cell Line”,J. Immunol.,144(12):4703-4711 (Jun. 15, 1990).
R. O'Connor et al, “Growth Factor-Dependent Differentiation Along the Myeloid and Lymphoid Lineages in an Immature Acute T Lymphocytic Leukemia”,J. Immunol.,145(11):3779-3787 (Dec. 1, 1990) [O'Connor I].
R. O'Connor et al, “Growth Factor Requirements of Childhood Acute T-Lymphoblastic Leukemia: Correlation Between Presence of Chromosomal Abnormalities and Ability to Grow Permanently in Vitro”,Blood,77(7):1534-1545 (Apr. 1, 1991).
A. Cesano et al, “Homing and Progression Patterns of Childhood Acute Lymphoblastic Leukemias in Severe Combined Immunodeficiency Mice”,Blood,77(11):2463-2474 (Jun. 1, 1991).
A. Cesano et al, “Establishment of a Karyotypically Normal Cytotoxic Leukemic T-Cell Line from a T-All Sample Engrafted in SCID Mice”,Blood,,81(10):2714-2722 (May 15, 1993).
A. Cesano et al, “Effect of Human Interleukin 3 on the Susceptibility of Fresh Leukemia Cells to Interleukin-2-Induced Lymphokine Activated Killing Activity”,Leukemia,6(6):567-573 (Jun. 1992).
A Cesano et al, “Cytokine Modulation of the Susceptibility of Acute T-Lymphoblastic Leukemia Cell Lines to LAK Activity”,Leukemia,7(3):404-409 (Mar. 1993).
A. Cesano et al, “Mechanisms of MHC-Non-Restricted Lysis in Two Human Killer T Cell Lines”,Nat. Immun.,11(5):288-289 (Oct. 1992).
A. Cesano et al, “Two Unique Human Leukemia T-Cell Lines Endowed with a Stable Cytotoxic Function and a Different Spectrum of Target Reactivity Analysis and Modulation of Their Lytic Mechanisms”,In Vitro Cell Dev. Biol.,28A:648-656 (Sep.-Oct. 1992).
A. Cesano et al, “Inducible Expression of Granulocyte-Macrophage Colony-Stimulating Factor, Tumor Necrosis Factor-&agr;, and Interferon-&ggr; in Two Human Cytotoxic Leukemic T-Cell Lines”,In Vitro Cell Dev. Biol.,28A:657-662 (Sep.-Oct. 1992).
A Cesano et al, “The Severe Combined Immunodeficient (SCID) Mouse as a Model for Human Myeloid Leukemias”,Oncogene,7:827-836 (May 1992).
A Cesano et al, “Treatment of Experimental Glioblastoma with a Human Major Histocompatibility Complex Nonrestricted Cytotoxic T Cell Line”, 55:96-101 (Jan. 1, 1995).
A. Cesano et al, “An Effective and Safe Marrow Purging Strategy Using a Lethally Irradiated Killer T Cell Clone”, inAdvances in Bone Marrow Purging and Processing,Fourth International Symposium, pp. 165-173 (Oct. 1994).
A. Cesano et al, “Cellular and Molecular Mechanisms of Activation of MHC Nonrestricted Cytotoxic Cells by IL-12”,J. Immunology,151:2943-2957 (Sep. 1993).
P. Greenberg et al, “Effector Mechanisms Operative in Adoptive Therapy of Tumor-Bearing Animals: Implications for the Use of Interleukin-2”,J. Biol. Resp. Modifiers,3(5):455-461 (1984).
J. Klarnet et al, “Helper-Independent CD8+Cytotoxic T Lymphocytes Express IL-1 Receptors and Require IL-1 for Secretion of IL-2”,J. Immunol.,142(7):2187-2191 (Apr. 1, 1989).
M. Cheever et al, “Potential Uses of Interleukin 2 in Cancer Therapy”,Immunobiol.,172:365-382 (1986).
“First AIDS Gene-Transfer Clinical Comes Before RAC”,Biotechnology Newswatch,11(22):1-3 (Nov. 18, 1991).
“RAC Phases Out Human Gene Therapy Unit; Approves Six New Protocols”Biotechnology Newswatch,12(4):9-10 (Feb. 17, 1992).
D. Ojcius et al, “Cell-Mediated Killing: Effector Mechanisms and Mediators”,Cancer Cells,2(5):138-145 (May 1990).
E. Grimm et al, “Lymphokine-Activated Killer Cell Phenomenon: Lysis of Natural Killer-Resistant Fresh Solid Tumor Cells by Interleukin 2-Activated Autologous Human Peripheral Blood Lymphocytes”
Cesano Alessandra
Rovera Giovanni
Santoli Daniela
Howson and Howson
Schwadron Ronald B.
The Wistar Institute of Anatomy and Biology
LandOfFree
Method of preventing cancer recurrence does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of preventing cancer recurrence, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of preventing cancer recurrence will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3189452